ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Realm Therapeutics shares halved after failure of Phase 2 study
August 16, 2018Shares in the London-listed Realm Therapeutics plummeted on Monday after the company reported that a Phase II study of the experimental drug PR022 had failed to meet its primary endpoint in people with atopic dermatitis. -
Realm Therapeutics Flunks PhII Trial for Conjunctivitis Drug
March 13, 2018Realm Therapeutics, Inc., based in Malvern, Pennsylvania, announced today that its PR013, failed to show efficacy in its Phase II trial for allergic conjunctivitis
Pharma Sources Insight January 2025
